Current and future prospects for anticoagulant therapy: Inhibitors of factor Xa and factor IIa

被引：57

作者：

Harenberg, Job ^{[1
]}

Wehling, Martin ^{[1
]}

机构：

[1] Heidelberg Univ, Fac Med, D-68167 Mannheim, Germany

来源：

SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2008年 / 34卷 / 01期

关键词：

thromboembolism; factor Xa inhibitor; factor IIa inhibitor; anticoagulants; clinical trial;

D O I：

10.1055/s-2008-1066023

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Indirect systemic and direct oral factor Xa and direct oral factor IIa inhibitors with improved pharmacologic profiles compared with heparins and vitamin K antagonists are currently in clinical development. This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran). Specifically, the results of dose-finding studies for the prevention of venous thromboembolism after elective orthopedic surgery, the results of dose-finding studies for treatment of acute venous thromboembolism including prolonged prophylaxis of recurrent events, and the designs of ongoing clinical trials are reviewed.

引用

收藏

页码：39 / 57

页数：19

相关论文

共 42 条

[21] Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran [J].

Harenberg, J ;

Joerg, I ;

Weiss, C .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (03) :173-177

[22]

HARENBERG J, 2008, IN PRESS EUR J CLIN

[23]

HARENBERG J, 2007, BLOOD, V110

[24] Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran [J].

Harenberg, Job ;

Joerg, Ingrid ;

Weiss, Christel .

INTERNATIONAL JOURNAL OF TOXICOLOGY, 2006, 25 (03) :165-169

[25] Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide [J].

Herbert, JM ;

Hérault, JP ;

Bernat, A ;

van Amsterdam, RGM ;

Lormeau, JC ;

Petitou, M ;

van Boeckel, C ;

Hoffmann, P ;

Meuleman, DG .

BLOOD, 1998, 91 (11) :4197-4205

[26] Beyond unfractionated heparin and warfarin - Current and future advances [J].

Hirsh, Jack ;

O'Donnell, Martin ;

Eikelboom, John W. .

CIRCULATION, 2007, 116 (05) :552-560

[27] Biochemical and pharmacological profiles of YM150, an oral direct factor Xa inhibitor. [J].

Iwatsuki, Yoshiyuki ;

Shigenaga, Takeshi ;

Moritani, Yumiko ;

Suzuki, Mami ;

Ishihara, Tsukasa ;

Hirayama, Fukushi ;

Kawasaki, Tomihisa .

BLOOD, 2006, 108 (11) :273A-273A

[28] Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases [J].

Kubitza, Dagmar ;

Haas, Sylvia .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (08) :843-855

[29] The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement [J].

Lassen, M. R. ;

Davidson, B. L. ;

Gallus, A. ;

Pineo, G. ;

Ansell, J. ;

Deitchman, D. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) :2368-2375

[30] Hepatic findings in long-term clinical trials of ximelagatran [J].

Lee, WM ;

Larrey, D ;

Olsson, R ;

Lewis, JH ;

Keisu, M ;

Auclert, L ;

Sheth, S .

DRUG SAFETY, 2005, 28 (04) :351-370

← 1 2 3 4 5 →